Evidence map›Paper›PMID 36914068›Full record

SynthesisIndian heart journal

SGLT2 inhibitors and cardiovascular outcomes in heart failure with mildly reduced and preserved ejection fraction: A systematic review and meta-analysis.

Mainak Banerjee, Rimesh Pal, Kirthana Nair, Satinath Mukhopadhyay

Abstract readMeta-AnalysisSystematic Review
PubMed Full text at PMC Publisher
In one paragraph

Synthesis in Indian heart journal. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers, 4 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
25citing papers in PubMed, 4 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

25 citing papers in PubMed, 4 syntheses or guidelines pooled it.

  1. Pooled it
  2. Guideline
  3. Pooled it
  4. Pooled it
  5. Trial
  6. Review
  7. Article
  8. Type 2 diabetes mellitus.Nature reviews. Disease primers · 2026
    Review
  9. Article
  10. Article
  11. Review
  12. Review
  13. Article
  14. Article
  15. Review
  16. Review
  17. Article
  18. Article
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Mainak BanerjeeDepartment of Endocrinology, Institute of Postgraduate Medical Education and Research, Kolkata, 700020, India. Electronic address: mainak18y@gmail.com.
Rimesh PalDepartment of Endocrinology, Postgraduate Institute of Medical Education and Research, Chandigarh, 160012, India.
Kirthana NairDepartment of Endocrinology, Postgraduate Institute of Medical Education and Research, Chandigarh, 160012, India.
Satinath MukhopadhyayDepartment of Endocrinology, Institute of Postgraduate Medical Education and Research, Kolkata, 700020, India. Electronic address: satinath.mukhopadhyay@gmail.com.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

aimTo provide a pooled effect of sodium-glucose cotransporter-2 inhibitors (SGLT2i) on cardiovascular outcomes in patients with heart failure with preserved ejection fraction (HFpEF: ≥50%) or/and mildly reduced EF (HFmrEF: 41-49%) regardless of baseline diabetes.

methodsWe systemically searched PubMed/MEDLINE, Embase, Web of Science databases and clinical trial registries using appropriate keywords till August 28, 2022, to identify randomized controlled trials (RCTs) or post-hoc analysis of RCTs, reporting cardiovascular death (CVD) and/or urgent visits/hospitalization for heart failure(HHF) in patients with HFmrEF/HFpEF receiving SGLTi vs. placebo. Hazard ratios (HR) with 95% confidence intervals (CI) for outcomes were pooled together using generic inverse variance method with fixed-effects model.

resultsWe identified six RCTs, pooling data retrieved from 15,769 patients with HFmrEF/HFpEF. Pooled analysis showed that compared to placebo, SGLT2i use was significantly associated with improved CVD/HHF outcomes in HFmrEF/HFpEF (pooled HR 0.80, 95% CI: 0.74, 0.86, p < 0.001, I

conclusionsThis meta-analysis established the place of SGLT2i as a foundational therapy among patients with HF with preserved and mildly reduced EF regardless of diabetes.

Indexed as

Diabetes MellitusHeart FailureSodium-Glucose Transporter 2 InhibitorsCause of DeathHumansPrognosisRisk FactorsStroke VolumeSodium-Glucose Transporter 2 InhibitorsDapagliflozinEmpagliflozinHeart failureSGLT2 inhibitorsSotagliflozinT2DM

Identifiers

PMID36914068
PMCPMC10123444

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.